Realizing he wasn’t good enough to make a career out of playing rugby or soccer, Steve went to medical school. Training as an academic hematologic oncologist in London and working as a clinician scientist at Barts and The London before joining the pharmaceutical industry in 2000, Steve was always motivated to have science drive the discovery of novel therapies. In London, he ran a clinical practice treating patients with leukemias and lymphomas in a research-focused environment, ran a research laboratory doing both basic and translational research and taught hematology to medical students. After two years of leading the clinical development of Sutent® for Pharmacia/SUGEN, he joined Genentech where he became vice president of hematology/oncology, playing a significant role in the development of key products such as Perjeta®, Kadcyla® and Erivedge® as well as other molecules in the company’s oncology portfolio. He then led the development of imetelstat, a first-in-class telomerase inhibitor, at Geron where he served as head of research and development and chief medical officer. Following his time at Geron, Steve served as president of Onkaido Therapeutics, a Moderna Venture focusing on discovery and development of mRNA therapeutics for cancer. During his 17 years in the biotechnology industry, Steve has worked with small molecules, antibodies, antibody-drug conjugates, DNA oligonucleotides and mRNA platforms and has driven multiple industry and industry-academia collaborations as part of the mission to provide better drugs for patients with cancer. He has a passion for building and leading high-functioning teams doing groundbreaking cancer research.
Steve graduated with bachelor of medicine and bachelor of surgery degrees (MB ChB) and a doctorate of medicine (M.D.) from the University of Birmingham, U.K. He is a fellow of both the Royal College of Physicians (FRCP) of London and the Royal College of Pathologists (FRCPath), U.K. He has over 100 peer-reviewed publications spanning cell biology, drug discovery, drug development and patient care, and is a named inventor on several patents. He now watches more soccer than he plays.
What is Stephen Michael Kelsey's net worth?
The estimated net worth of Stephen Michael Kelsey is at least $11.67 million as of October 14th, 2024. Dr. Kelsey owns 264,408 shares of Revolution Medicines stock worth more than $11,665,681 as of January 5th. This net worth evaluation does not reflect any other investments that Dr. Kelsey may own. Additionally, Dr. Kelsey receives an annual salary of $812,170.00 as President, Research & Development at Revolution Medicines. Learn More about Stephen Michael Kelsey's net worth.
How old is Stephen Michael Kelsey?
What is Stephen Michael Kelsey's salary?
As the President, Research & Development of Revolution Medicines, Inc., Dr. Kelsey earns $812,170.00 per year. The highest earning executive at Revolution Medicines is Dr. Mark A. Goldsmith Ph.D., CEO, President & Chairman, who commands a salary of $1,120,000.00 per year. Learn More on Stephen Michael Kelsey's salary.
How do I contact Stephen Michael Kelsey?
Has Stephen Michael Kelsey been buying or selling shares of Revolution Medicines?
Stephen Michael Kelsey has not been actively trading shares of Revolution Medicines during the last quarter. Most recently, Stephen Michael Kelsey sold 16,666 shares of the business's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $49.49, for a transaction totalling $824,800.34. Following the completion of the sale, the insider now directly owns 264,408 shares of the company's stock, valued at $13,085,551.92. Learn More on Stephen Michael Kelsey's trading history.
Who are Revolution Medicines' active insiders?
Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?
In the last twelve months, Revolution Medicines insiders bought shares 1 times. They purchased a total of 1,304,347 shares worth more than $59,999,962.00. In the last twelve months, insiders at the sold shares 27 times. They sold a total of 238,507 shares worth more than $11,009,037.57. The most recent insider tranaction occured on December, 16th when COO Margaret A Horn sold 4,329 shares worth more than $196,536.60. Insiders at Revolution Medicines own 8.0% of the company.
Learn More about insider trades at Revolution Medicines. Information on this page was last updated on 12/16/2024.
